Dozens of people are getting one third dose of the COVID-19 vaccine in the United States, this time with small adjustments to combat a version of the virus with mutations.
Vaccines currently available in the United States offer great protection. But new studies of experimental updates of vaccines Modern i Pfizer they represent a first step towards an alternative if the virus becomes resistant to today’s vaccines.
“We need to get ahead of the virus,” said Dr. Nadine Rouphael of Emory University, who is helping lead the study of the new version of Moderna. “We know what it’s like to be behind the virus.”
It is unclear whether the protection offered by vaccines will be diluted, Making new vaccines necessary, however, “realistically, we want COVID to become just a cold.”
Viruses are constantly evolving and there is already a variant spreading that is more easily detected initially detected in Britain. Fortunately, it can be prevented with vaccines.
But it is feared that the first generation of vaccines will not be as effective against another variant that has emerged in South Africa. All laboratories that produced vaccines are looking for ways to fight the B.1.351 virus if necessary. Experimental doses of Moderna and Pfizer are now being tested.
Emory University, on the outskirts of Atlanta, asked people who participated in the first vaccine studies to help with this update.
We recommend:
Volunteer Cole Smith said he didn’t have to think too much about it.
“The first was a huge success and millions of people are being vaccinated,” Smith told the Associated Press. “If we help people with the first one, why not volunteer to help with this new vaccine?”
Researchers at Emory and three medical centers are also recruiting volunteers who have not received any vaccine against COVID-19[feminine.
L’objectiu no és només determinar si la tercera dosi de Moderna funciona contra la nova variant de virus. També es tracta de comprovar si dues dosis de la nova vacuna serien suficients. O una de cada vacuna. O si es pot combinar les dues vacunes en un.
L’Administració d’Aliments i Medicines dels Estats Units va autoritzar a Pfizer i al seu soci, el laboratori alemany BioNTech, perquè facin experiments similars amb la seva vacuna.
Les vacunes de Moderna i Pfizer, igual que la majoria de les vacunes que s’estan fent servir en tot el món, entrenen a el cos perquè reconegui la proteïna S de la capa externa de l’coronavirus.
És comú que hi hagi mutacions en els virus, però si es produeixen massa, poden escapar a un sistema immunològic pensat per detectar intrusos.
El millor és que és bastant senzill actualitzar les vacunes de Moderna i de Pfizer.
Els estudis llançats aquest mes abasten pocs centenars de persones, comparat amb els milers usades per assajar les vacunes originals.